Humoral immune response after SARS-CoV-2 vaccination in cladribine-treated multiple sclerosis patients

Humoral immune response after SARS-CoV-2 vaccination in cladribine-treated multiple sclerosis patients

Multiple sclerosis immunomodulatory treatments such as cladribine, which affects both B- and T-lymphocytes, can potentially alter the humoral response to SARS-CoV-2 vaccination. This monocenter retrospective study reports on anti-SARS-CoV-2 IgG antibody response in cladribine treated MS patients and...

Full description

Bibliographic Details
Main Authors: M. Mimpen, D. Kreiter, T. Kempkens, S. Knippenberg, R. Hupperts, O. Gerlach
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Vaccine: X
Subjects:
Multiple sclerosis
COVID-19
Cladribine
Vaccination
Online Access:http://www.sciencedirect.com/science/article/pii/S2590136224000184

Similar Items

Similar Items